• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Elagolix
    1 Drug classified under this active ingredient


    All the Active Ingredient Drugs

    ORILISSA
    AbbVie
    RX
    not in the basket chart
    ORILISSA

    GnRH Antagonist. Elagolix (as sodium) 150 mg, 200 mg.
    F.C. TABS: 28×150mg, 56×200mg. Init. tmt. with 150 mg×1/d, max. tmt. duration-24 mnths.
    Consider initiat. tmt. with 200 mg×2/d max. tmt. duration- 6 mnths., with coexist. cond.- dyspareunia.
    Init. tmt. with Elagolix 150 mg×1/d. Use of 200 mg×2/d is not recommended, max. tmt. duration- 6 mnths., with coexist. cond.- moder. hep. impair. (Child-Pugh Class B).
    Hep. Impair.: No dosage adjust. of Elagolix is require. in women with mild hep. impair. (Child-Pugh A). Elagolix 150 mg×1/d is recomm. for women with moder. hep. impair. (Child-Pugh B) with the duration of tmt. limited to 6 mnths. Use of Elagolix 200 mg×2/d is not recommend. for women with moder. hep. impair. See lit.
    Management of moder.–seve. pain assoc. with endometriosis.
    C/I: With Hypersens. Preg. Women with known osteoporosis. Women with sev. hep. impair (Child-Pugh C).

    IL-ELAG-200014-june2020

    CLOSE